The orexin-1 antagonist SB-334867 blocks antipsychotic treatment-emergent catalepsy: Implications for the treatment of extrapyramidal symptoms

Schizophrenia Bulletin

Volumn 33, Issue 6, 2007, Pages 1291-1297

  Rasmussen, Kurt ^a   Hsu, Mei Ann ^a   Noone, Stephen ^a   Johnson, Bryan G ^a   Thompson, Linda K ^a   Hemrick Luecke, Susan K ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotics; Catalepsy; Haloperidol; Olanzapine; Orexin; Risperidone

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; 3,4 DIHYDROXYPHENYLACETIC ACID; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; OREXIN 1 ANTAGONIST; OREXIN 1 RECEPTOR; PROLACTIN; RECEPTOR BLOCKING AGENT; RISPERIDONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BRAIN LEVEL; CATALEPSY; CORPUS STRIATUM; DRUG EFFECT; DRUG SCREENING; EXPLORATORY BEHAVIOR; EXTRAPYRAMIDAL SYMPTOM; LOCOMOTION; MALE; NEUROCHEMISTRY; NEUROENDOCRINE SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BEHAVIOR, ANIMAL; BENZODIAZEPINES; BENZOXAZOLES; CATALEPSY; HALOPERIDOL; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LOCOMOTION; MALE; NEUROPEPTIDES; PROLACTIN; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; UREA;

EID: 35649028837     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbm087     Document Type: Article

References (25)

1. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573-585.
2. van den Pol AN, Gao XB, Obrietan K, Kilduff TS, Belousov AB. Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin. J Neurosci. 1998;18:7962-7971.
3. Piper DC, Upton N, Smith MI, Hunter AJ. The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci. 2000;12:726-730.
4. Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci. 2005;25:6716-6720.
5. Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med. 2007;13:150-155.
6. Fadel J, Deutch AY. Anatomical substrates of orexindopamine interactions: lateral hypothalamic projections to the ventral tegmental area. Neurosci. 2002;111:379-387.
7. Fadel J, Bubser M, Deutch AY. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci. 2002;22:6742-6746.
8. Korotkova TM, Sergeeva OA, Eriksson KS, Haas HL, Brown RE. Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. J Neurosci. 2003;23:7-11.
9. Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A. Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron. 2006;49:589-601.
10. Rasmussen K, Hsu M-A, Yang Y. The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy. Neuropsychopharmacology. 2007;32:786-792.
11. Fuller RW, Perry KW. Effects of buspirone and its metabolite, 1-(2-pyrimidinyl) piperazine, on brain monoamines and metabolites. J Pharmacol Exp Ther. 1989;248:50-56.
12. Moore NA, Tye NC, Axton MS, Risius FC. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther. 1992;262:545-551.
13. Calderon SF, Sanberg PR, Norman AB. Quinolinic acid lesions of rat striatum abolish D1- and D2-dopamine receptor-mediated catalepsy. Brain Res. 1988;450:403-407.
14. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci. 1983;3:1607-1619.
15. Arnt J. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol. 1995;283:55-62.
16. Karoum F, Chrapusta SJ, Egan MF. 3-methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex - reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem. 1994;63:972-979.
17. Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW. Neurochemical evidence for antagonismby olanzapine of dopamine, serotonin, alpha(1)-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl). 1996;124:87-94.
18. Kapur S, Langlois X, Vinken P, Megens AAHP, deCoster R, Andrews JS. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther. 2002;302:1129-1134.
19. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology. 2003;28:69-82.
20. Jaber M, Robinson SW, Missale C, Caron MG. Dopamine receptors and brain function. Neuropharmacology. 1996;35:1503-1519.
21. Hervieu GJ, Cluderay JE, Harrison DC, Roberts JC, Leslie RA. Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. Neuroscience. 2001;103:777-797.
22. Deutch AY, Lee MC, Iadarola MJ. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci. 1992;3:332-341.
23. Robertson GS, Matsumura H, Fibiger HC. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther. 1994;271:1058-1066.
24. Deutch AY, Duman RS. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neuroscience. 1996;70:377-389.
25. Deutch AY, Jackson LL, Bubser M. Disruption of orexin/hypocretin signaling blocks the effects of clozapine on the prefrontal cortex. Schizophr Bull. 2005;31:510.